Monday , December 18 2017
Home / Resources / Videos / Christophe Arbet-Engels, MD, Q4: Benefits of Empagliflozin

Christophe Arbet-Engels, MD, Q4: Benefits of Empagliflozin

Dr. Christophe Arbet-Engels talks about how the empagliflozin study results were very positive in terms of lowering A1c, and goes over the basics of how the new class of SGLT-2 inhibitor drugs work, removing excess glucose, inducing some weight loss, and that there is potential for a decrease in blood pressure as well.

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources